Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01.
Anticipation surrounds NeoGenomics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings History Snapshot
During the last quarter, the company reported an EPS beat by $0.01, leading to a 2.81% drop in the share price on the subsequent day.
Here's a look at NeoGenomics's past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
EPS Estimate
-0.01
-0.01
0.03
0.01
0
EPS Actual
0.03
0
0.04
0.05
0.03
Price Change %
-3.0%
-3.0%
3.0%
4.0%
18.0%
Tracking NeoGenomics's Stock Performance
Shares of NeoGenomics were trading at $5.8 as of August 08. Over the last 52-week period, shares are down 65.08%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
Analyst Insights on NeoGenomics
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on NeoGenomics.
With 3 analyst ratings, NeoGenomics has a consensus rating of Buy. The average one-year price target is $9.0, indicating a potential 55.17% upside.
Analyzing Analyst Ratings Among Peers
This comparison focuses on the analyst ratings and average 1-year ...